Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 15.19.
Forward PE Ratio (15.19) = Close Price ($74.82) / Consensus Forward EPS ($4.93)
FORWARD PE RATIO
15.19
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
-23.73%
vs the sector median at left
GE HealthCare Technologies Inc.
Market Cap
$33.80B
Forward PE Ratio
15.19
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $33.80B | 15.19 |
| ResMed Inc. (RMD)vs › | $33.58B | 20.81 |
| DexCom, Inc. (DXCM)vs › | $34.85B | 34.61 |
| Zoetis Inc. (ZTS)vs › | $32.59B | 12.35 |
| Centene Corp. (CNC)vs › | $32.12B | 13.54 |
| Biogen Inc. (BIIB)vs › | $32.03B | 17.40 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $31.61B | 36.30 |
| Waters Corporation (WAT)vs › | $30.72B | 28.18 |
| BioNTech SE (BNTX)vs › | $29.28B | N/A |
| Medline Inc. (MDLN)vs › | $28.97B | 22.71 |
Trailing P/E
21.7
reported TTM EPS
Forward P/E
15.2
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $4.93 implies +42.9% EPS growth vs the reported trailing $3.45.
At today's $74.82 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $4.93 | $4.90 – $5.00 | 12 | 15.2x |
| 2027-12-31 | $5.44 | $5.16 – $5.58 | 12 | 13.8x |
| 2028-12-31 | $6.03 | $5.40 – $6.39 | 9 | 12.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
